PubMed Health⌕ Search

Biomedical subjects

M J Fuller

Publications and source records attributed to M J Fuller.

4 recordsLinked to original sources
PubMed1997

Comprehensive reimbursement model: an alternative to fee-for-service reimbursement by blood centers.

"If we could first know where we are, and whither we are tending, we could then better judge what to do and how to do it." This quote from Abraham Lincoln epitomizes where SMF and its CRM hospital customers are today. The CRM has been received by SMF's hospital customers as a step in the right direction. Currently, it seems to be the best way to partner with hospitals by sharing risk in the current health care delivery system milieu. The CRM focus on patient outcomes will provide hospitals and blood centers a common goal. Modifications to the CRM will most certainly be necessary. With input from customers and the community over time, and flexibility from SMF, a revised model will evolve that will be even more mutually beneficial.

Blood Banks↗
PubMed1997

The 90s paradox: QA efforts reduce total quality.

The focus on "closing the window" of infectious risks in transfusion has concentrated limited health care resources on marginal increases in blood safety in the name of quality assurance (QA). Significant investments in testing and medical history additions have been made to restrict further any release of unsuitable blood and apheresis donations. As funds are used in a disproportionate manner with regard to these quality benefits, the depletion of resources precludes investment in quality enhancements (e.g. potency) other than safety, and actually may reduce quality over all. Although safety is an important element of quality, it is not the only element. Increasingly, blood center customers expect, but are unwilling to pay for, limited increases in product safety, such as anti-HCV 3.0 and HIV p24 antigen testing; they should be encouraging improved potency and efficacy for QA. In the future, blood service providers must demonstrate the value of additional QA activities--otherwise, they will not receive reimbursement. Total quality remains the objective goal. However, the investment in QA efforts must yield a benefit equal to, or greater than, investment in the quality assurance process.

Blood Transfusion↗